What Is Checkpoint Blockade Cancer Therapy?

Checkpoint blockade therapy is a form of cancer treatment that leverages the body’s immune system to combat malignant cells. The primary goal is to enhance the immune system’s natural ability to identify and eliminate cancer cells, which have developed ways to hide from it. This treatment uses a class of drugs called immune checkpoint inhibitors to help the immune system recognize and attack cancer.

The Immune System’s Natural Brakes

The immune system can distinguish between the body’s own healthy cells and harmful invaders like viruses or bacteria. A specialized type of white blood cell, known as a T-cell, is a primary actor in this defense system, identifying and launching attacks against threats. T-cells carry various protein molecules on their surface that help regulate the body’s immune response. These regulatory proteins function as “checkpoints.”

Their main function is to prevent immune responses from becoming too aggressive and attacking the body’s own tissues, which could lead to autoimmune diseases. Think of them as a car’s braking system; they slow down or stop the T-cell’s attack once a threat has been neutralized.

How Cancer Exploits Immune Checkpoints

Some cancers have developed a strategy to evade destruction by the immune system by taking advantage of these natural brakes. These cancer cells can produce specific proteins on their surface that act as signals to the T-cells. When T-cells come into contact with these proteins, the checkpoint system is engaged. This interaction sends a “stop” signal to the T-cells.

The T-cell receives the message that the cancer cell is not a threat and should be left alone, halting the immune attack before the cancer is destroyed. By exploiting these checkpoint pathways, a tumor can suppress the immune response in its immediate environment, allowing it to grow and spread.

The Mechanism of Checkpoint Blockade Therapy

Checkpoint blockade therapy works by disrupting the communication between cancer cells and T-cells. The drugs used in this treatment are a type of antibody designed to physically block the checkpoint proteins. By doing so, they prevent the “stop” signal from being delivered, effectively “releasing the brakes” on the T-cells and allowing them to proceed with their attack on the tumor. These drugs are administered intravenously.

Two of the most well-understood checkpoint pathways targeted by these therapies are CTLA-4 and PD-1/PD-L1. CTLA-4 is a checkpoint protein on T-cells that acts as an “off” switch to dampen the immune response. Drugs that block CTLA-4, such as ipilimumab, prevent this signal from being sent, leading to a more powerful and sustained activation of T-cells against cancer.

The PD-1/PD-L1 pathway is another major target. PD-1 is a checkpoint protein found on the surface of T-cells, while its partner, PD-L1, can be found on the surface of some cancer cells. When PD-1 and PD-L1 bind together, it deactivates the T-cell. Checkpoint inhibitor drugs can block either PD-1 (with drugs like pembrolizumab and nivolumab) or PD-L1 (with drugs like atezolizumab), preventing this interaction and permitting the T-cells to recognize and kill the tumor cells.

Cancers Treated and Patient Selection

Checkpoint blockade therapies were first approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma in 2011. Since then, their use has expanded. These treatments are now utilized for a range of cancers, including non-small cell lung cancer, kidney cancer, bladder cancer, and head and neck cancers. Research continues to explore their effectiveness in other malignancies.

Not every patient with these cancers will respond to checkpoint inhibitors. Therefore, doctors often use specific tests to help determine who is most likely to benefit. One common method involves testing the patient’s tumor for the presence of biomarkers, such as the PD-L1 protein. A higher level of PD-L1 expression on a tumor may suggest that the cancer is relying on this pathway to hide from the immune system, making it a better target for a PD-1/PD-L1 inhibitor.

Managing Immune-Related Side Effects

Because checkpoint blockade therapy energizes the immune system, it can sometimes cause T-cells to attack healthy tissues and organs, not just cancer cells. These side effects are known as immune-related adverse events (irAEs) and are different from those associated with traditional chemotherapy. The reactions are inflammatory in nature and can affect various parts of the body.

Common side effects include skin issues like rashes and inflammation of the colon, which can cause diarrhea. In some cases, more serious inflammation can occur in the liver, lungs, or endocrine glands. Medical teams can identify these side effects early. Management often involves using medications like steroids to suppress the overactive immune response. Nearly all patients experience some level of side effects, though they are often low-grade or moderate.

Hydroxychloroquine and Cancer: The State of the Research

Dane Particles: Structure, Role, and Infection in Hepatitis B

What Is the Prozac Activating Effect?